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*Corresponding Author. E-mail: frankpeacock@gmail.com, Twitter: @WFPeacock.Study objective: Assessing stroke risk associated with nonvalvular atrial ﬁbrillation depends on the evaluation of
patient characteristics and clinical features. Clinicians must determine that the net clinical beneﬁt from anticoagulation
therapy outweighs its risk, namely, bleeding. Risk assessment for stroke is commonly performed by calculating a
CHA2DS2-VASc (congestive heart failure/left ventricular dysfunction, hypertension, 75 years, diabetes mellitus,
previous stroke or transient ischemic attack or thromboembolism, vascular disease, aged 65 to 74 years, sex female)
score. It is possible that CHA2DS2-VASc scores also have a relationship with the incidence of major bleeding. We
examined the relationship between CHA2DS2-VASc scores and major bleeding in rivaroxaban users with nonvalvular
atrial ﬁbrillation.
Methods: Electronic medical records of more than 10 million patients from the Department of Defense Military Health
System were queried to identify patients with nonvalvular atrial ﬁbrillation who received rivaroxaban from January 1,
2013, to June 30, 2015. Baseline characteristics of the study population were described by CHA2DS2-VASc scores and
major bleeding status; major bleeding incidence was evaluated by CHA2DS2-VASc score category and for each CHA2DS2-
VASc component.
Results: Overall, 44,793 patients met the inclusion criteria for this analysis. The major bleeding incidence rate was
2.84 (95% conﬁdence interval 2.69 to 3.00) per 100 person-years. The incidence of major bleeding increased from
0.30 to 5.40 per 100 person-years among patients with a CHA2DS2-VASc score of 0 to 5 or higher, respectively. Fatal
outcomes among patients with major bleeding were positively correlated with CHA2DS2-VASc scores; patients with
higher scores had higher mortality rates. The CHA2DS2-VASc component with the highest major bleeding incidence was
for vascular disease, 5.69 (95% conﬁdence interval 5.18 to 6.24) per 100 person-years.
Conclusion: Higher CHA2DS2-VASc scores are associated with increased incidence of major bleeding in nonvalvular
atrial ﬁbrillation patients receiving rivaroxaban. [Ann Emerg Med. 2016;-:1-10.]
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Background
Atrial ﬁbrillation is the most common cardiac
arrhythmia1-3 and is associated with signiﬁcant morbidity
and mortality related to stroke and thromboembolism.2
The prevalence of atrial ﬁbrillation is estimated to be 0.1%
in persons younger than 55 years and as high as 10% in
those older than 85 years.1,3 Incidence of atrial ﬁbrillation
is expected to increase as the population ages and the
occurrence of risk factors increases.1-3
Themost devastating and potentially fatal consequence of
atrial ﬁbrillation is ischemic stroke.1,3,4 Strokes in atrial- : - 2016ﬁbrillation patients are often more severe than other types of
stroke, withmore instances of disability or death.5-7 Assessing
the atrial ﬁbrillation stroke risk depends on the evaluation of
patient characteristics, comorbidities, and clinical
features.1,2,8 Older age and history of stroke, transient
ischemic attack, or thromboembolism are the strongest
independent predictors of stroke in atrial ﬁbrillation
patients.1,2,5 Additionally, diabetes, female sex, vascular
disease, and congestive heart failure are associated with
elevated stroke risk among persons with atrial ﬁbrillation.1,2,9
Risk assessment scores have been developed to quantify
stroke risk in patients with atrial ﬁbrillation. The EuropeanAnnals of Emergency Medicine 1
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What is already known on this topic
The decision to use anticoagulants in atrial
ﬁbrillation is based on an assessment of the
competing risks of stroke and excessive bleeding.
What question this study addressed
Does the CHA2DS2-VASc (congestive heart failure/
left ventricular dysfunction, hypertension, 75 years,
diabetes mellitus, previous stroke or transient
ischemic attack or thromboembolism, vascular
disease, aged 65 to 74 years, sex female) validated
stroke risk assessment tool for nonvalvular atrial
ﬁbrillation correlate with major bleeding in patients
receiving rivaroxaban?
What this study adds to our knowledge
In a Department of Defense data set with 44,793
patients, increasing stroke risk score correlated with
more frequent major bleeding, especially in patients
with high vascular disease components to the score.
How this is relevant to clinical practice
Expect more patients to seek emergency care for
major bleeding while receiving rivaroxaban for
nonvalvular atrial ﬁbrillation as stroke risk increases.Society of Cardiology,8 the American College of
Cardiology and American Heart Association,9 and the
National Institute for Health and Care Excellence10
recommend the use of CHA2DS2-VASc (congestive heart
failure/left ventricular dysfunction, hypertension, 75
years, diabetes mellitus, previous stroke or transient
ischemic attack or thromboembolism, vascular disease, aged
65 to 74 years, sex female)11 as the preferred risk-scoring
method to gauge stroke risk in atrial ﬁbrillation patients.1,12
Using stroke risk scores allows targeted interventions to aid
in the prevention of thrombotic events, namely, through
the use of oral anticoagulants.1,9 Clinical studies provide
evidence of therapeutic options at a population level.
However, in clinical practice, treatment options must be
considered from the perspective of the individual patient
and require strategic personalization that considers the
unique constellation of risks and beneﬁts, of which few are
typically represented in clinical trials.
With the availability of anticoagulation that does not
require heparin bridging, consequent to medications that
are effective within 2 hours, the need for hospitalization for
anticoagulation is rapidly declining. Thus, in selected2 Annals of Emergency Medicinepatients the emergency physician will need to choose
between a hospital admission of little beneﬁt (besides
administration of a daily pill) or discharge with the patient
receiving oral anticoagulation. Knowledge of the risks and
beneﬁts of oral anticoagulants is becoming critical. In
treating atrial ﬁbrillation patients at risk for stroke,
clinicians must determine whether the net clinical beneﬁt
from anticoagulation therapy outweighs its risk, namely,
bleeding.1,5
Importance
Clinicians must weigh many factors when deciding
whether a patient should receive anticoagulation therapy.
Assessing the risk for any given patient requires a
personalized assessment of his or her risk of stroke without
therapy versus the risk of bleeding with therapy.
CHA2DS2-VASc scores have been proven to quantify
stroke risk8-12; these scores may also have a relationship
with bleeding risk. Understanding the relationship between
CHA2DS2-VASc scores and the incidence of major
bleeding may provide another valuable tool in the clinical
decisionmaking process.
Goals of This Investigation
The current evaluation was derived from an ongoing,
5-year pharmacovigilance study, designed to provide
longitudinal safety data by actively obtaining information
associated with rivaroxaban use in the postapproval setting,
complementary to the clinical trial data and that being
collected by the spontaneous adverse event reporting
process. Our objective for this analysis was to examine the
relationship between CHA2DS2-VASc scores and the
incidence of nontrauma-related major bleeding in
rivaroxaban users with nonvalvular atrial ﬁbrillation.MATERIALS AND METHODS
Study Design
This observational study used a retrospectively assembled
cohort of patients diagnosed with nonvalvular atrial
ﬁbrillation. Within this population, patients who were
exposed to rivaroxaban were included in the study analyses.
Selection of Participants
The patient population for this analysis was derived
from the US Department of Defense electronic medical
records system. The Department of Defense Military
Health System covers military service members and their
families and represents one of the largest US health systems,
with nearly 10 million active patients.13 The system is not
linked with data streams from Veterans Affairs because itVolume -, no. - : - 2016
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therefore, this study population does not contain data from
the Veterans Affairs patient population.
The Military Health System population has a relatively
high representation of elderly, with patients older than 65
years making up more than 20% of the total14 compared
with 13% of the overall US population.15 The Military
Health System databases consist of longitudinal electronic
medical records that are continually updated and contain
administrative, pharmacy, laboratory, and clinical data.
Inpatient and outpatient data are integrated, which ensures
robust capture of medical encounters, including major
bleeding events, along with associated pharmacy data. As
described previously, the Department of Defense health care
system is paperless, and all patient-level medical information
and clinical data are kept in one electronic format. Incoming
records are checked against a set of minimum standards for
quality to ensure the integrity of the data, and duplicate
records are removed before analysis.16
Patients insured through the Military Health System are
not required to use military medical facilities. In fact, many
insured members use their Military Health System coverage
to obtain care in nonmilitary (civilian) facilities. If a patient
insured by the Military Health System is hospitalized
anywhere for any reason, the claim and related clinical
information are routed back to the Department of Defense
Military Health System databases, thus limiting the
probability of undetected events.Study Interval and Patient Eligibility
This study analyzed data from the 2.5-year observation
period of January 1, 2013, to June 30, 2015, among patients
with nonvalvular atrial ﬁbrillation diagnoses who were
receiving rivaroxaban. The information included in the
analyses for this study cohort was identiﬁed through relevant
International Classiﬁcation of Diseases, Ninth Revision,
Clinical Modiﬁcation (ICD-9-CM) diagnosis and procedure
codes and Common Procedure Terminology and
Healthcare Common Procedure Coding System procedure
codes that were listed in any available procedure ﬁeld within
any medical encounter record. The ICD-9 code 427.31 was
used to identify patients with atrial ﬁbrillation, and a
separate set of diagnosis and procedure codes was used to
further distinguish nonvalvular atrial ﬁbrillation patients.
All patients meeting the deﬁnition for nonvalvular atrial
ﬁbrillation were included, regardless of incident or
prevalent rivaroxaban usage, as long as the patient was
identiﬁed as having nonvalvular atrial ﬁbrillation before or
concurrent with rivaroxaban usage. Patients were evaluated
for major bleeding during the study period or censored atVolume -, no. - : - 2016the earliest occurrence of any of 4 events: a major bleeding
event, death, loss of Military Health System eligibility, or
end of study.Outcome Measures
The primary outcome of interest was major bleeding, as
deﬁned by the Cunningham algorithm.17 Cunningham
et al17 developed a validated database algorithm using
administrative data for identiﬁcation of major bleeding
events that result in a hospitalization. Per the algorithm,
bleeding events determined to be trauma related were
excluded. The Cunningham algorithm identiﬁes bleeding-
related hospitalizations from the primary discharge
diagnosis, with the types of major bleeding events
considered including gastrointestinal bleeding, hemorrhagic
strokes, other intracranial bleeding events, and bleeding at
other sites. The use of bleeding diagnoses showed a positive
predictive value of 89% to 99% in the validation study by
Cunningham et al,17 and this algorithm has been used in
other clinical studies to identify serious bleeding
events.16,18-25
Although the Cunningham algorithm is a
comprehensive and validated case-ﬁnding tool, the
deﬁnition for major bleeding in this study is not an exact
match with the clinical trial (Rivaroxaban Once Daily Oral
Direct Factor Xa Inhibition Compared with Vitamin K
Antagonism for Prevention of Stroke and Embolism Trial
in Atrial Fibrillation [ROCKET-AF]) deﬁnition because
the algorithm is applied retrospectively and relies on the
information available in the electronic medical record. As a
comparison, the clinical trial deﬁnition of major bleeding
was deﬁned as clinically overt bleeding associated with a
decrease in hemoglobin level of 2 g/dL or more, or a
transfusion of 2 or more units of packed RBCs or whole
blood, or major bleeding in a critical site, or a fatal
outcome.26
Major bleeding events were included if they occurred
anytime during rivaroxaban exposure plus 7 days
postdiscontinuation. The drug exposure period for patients
was captured from the initiation date of rivaroxaban therapy
until its discontinuation. For patients who experienced a
major bleeding event, data were collected on major bleeding
management, fatal outcomes, and discharge status.Primary Data Analysis
Descriptive statistics are presented on patient
demographics, comorbidities, rivaroxaban usage,
hospitalization and bleeding-event management data,
bleeding-event characteristics, and outcomes. Because the
database contained limited data on smoking, alcohol use,Annals of Emergency Medicine 3
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presented.
Categorical variables were summarized with counts and
proportions. Mean values, along with SD, were calculated
for continuous variables. No a priori hypothesis testing was
planned or performed.
The incidence rates of major bleeding plus 95%
conﬁdence intervals (CIs) were calculated using a person-
time approach: the number of patients with a ﬁrst episode
of major bleeding divided by the exposure time at risk,
reported in person-centuries. Subsequent major bleeding
events in patients experiencing multiple bleeding events
were not included in the incidence rate calculations or
related analyses. Baseline characteristics of the study
population were stratiﬁed and evaluated by CHA2DS2-
VASc scores and major bleeding status (major bleeding
versus no major bleeding).
CHA2DS2-VASc scores were calculated for each study
patient, using the schema presented in Table 1, with age
deﬁned at bleeding for major bleeding cases and at the end
of study participation for patients without major bleeding.
Major bleeding incidence rates were also calculated by
bleeding site and for each CHA2DS2-VASc score category.
Comorbidities were deﬁned within a 6-month period
before the date of bleeding event for major bleeding cases
and at the end of study participation for patients without
major bleeding. The major bleeding incidence rate was
studied by score category (0 to 5), as well as by each
component of CHA2DS2-VASc scoring.
Data captured for this study were subject to multiple
quality control measures. The Department of Defense
houses all of the queryable data sources within the Military
Health System Data Repository. Incoming records
transmitted to the repository are veriﬁed to be constructed
in a standardized format respective to the data source, and
all data elements are inspected for acceptable formats and to
ensure that they are devoid of improbable values. Records
that meet the minimum standards are then processedTable 1. CHA2DS2-VASc schema and scoring.
Risk Factor Points*
Congestive heart failure/left ventricular dysfunction 1
Hypertension 1
75 y 2
Diabetes mellitus 1
Stroke/TIA/thromboembolism history 2
Vascular disease history 1
65–74 y 1
Sex category, female 1
TIA, Transient ischemic attack.
*Maximum of 9 points.
4 Annals of Emergency Medicineaccording to a set of published business rules and
transformed into standardized data sets.
The Military Health System Data Repository is a SAS-
computable environment, and all data sets within the
repository are linked by a common, unique patient
identiﬁer. Two SAS programmers worked in parallel to
independently draft code necessary to query and analyze all
data pertinent to this study.
This postmarketing safety surveillance study was part of
a postmarketing commitment, which was funded by
Janssen Scientiﬁc Affairs, LLC and Bayer HealthCare. The
study protocol, including the ascertainment method of
major bleeding events, was reviewed and approved by the
Food and Drug Administration before its ﬁnalization. The
research data were derived from an approved Naval Medical
Center, Portsmouth, Virginia institutional review board
protocol, and the research was conducted in compliance
with federal and state laws, including the Health Insurance
Portability and Accountability Act of 1996.
Health ResearchTx, LLC carried out all analyses with
SAS (version 9.2; SAS Institute, Inc., Cary, NC).RESULTS
A total of 44,793 rivaroxaban users with nonvalvular atrial
ﬁbrillation were identiﬁed during the study interval. During
this 2.5-year period, 1,352 major bleeding events in 1,293
patients were identiﬁed. The overall major bleeding
incidence rate, based on a patient’s ﬁrstmajor bleeding event,
was 2.84 (95% CI 2.69 to 3.00) per 100 person-years.Characteristics of Study Subjects
Table 2 shows baseline characteristics of the study cohort
stratiﬁed by CHA2DS2-VASc score category and major
bleeding status. Across the entire study cohort, patients with
major bleeding had a median CHA2DS2-VASc score of 4
(quartile 1, quartile 3: 4, 5) compared with 3 (quartile 1,
quartile 3: 2, 5) among those without major bleeding.
Consistent with nonvalvular atrial ﬁbrillation guideline
recommendations, themajority of patients (90.7%) receiving
rivaroxaban had a CHA2DS2-VASc score of 2 or greater.
Patients with a CHA2DS2-VASc score less than 2 (<10% of
the total cohort) represented a disproportionately male
population, with less than 10% women. This is not
unexpected because female patients with one additional risk
factorwould be classiﬁed as having aCHA2DS2-VASc greater
than or equal to 2. However, it is not entirely clear why these
patients with low risk received rivaroxaban therapy.
The highest proportion of the study population was
patients with a CHA2DS2-VASc score greater than 4
(n¼11,760; 26.3%). Overall, 72% of all patients had aVolume -, no. - : - 2016
Table 2. Baseline characteristics of rivaroxaban users with nonvalvular atrial ﬁbrillation by major bleeding status and CHA2DS2-VASc score.
Patient Characteristics
CHA2DS2-VASc Score
All Patients, N[44,793 0, N[1,051 1, N[3,102 2, N[8,183 3, N[10,903 4, N[9,794 ‡5, N[11,760
MB
n[1,293
No MB
n[43,500
MB
n[2
No MB
n[1,049
MB
n[19
No MB
n[3,083
MB
n[75
No MB
n[8,108
MB
n[204
No MB
n[10,699
MB
n[358
No MB
n[9,436
MB
n[635
No MB
n[11,125
Age, mean (SD), y* 78.7 (7.9) 76.2 (10.0) 59.5 (0.7) 53.0 (10.5) 62.6 (7.2) 63.9 (8.5) 73.0 (9.2) 73.7 (9.7) 76.5 (8.0) 77.2 (8.8) 79.6 (7.2) 78.8 (7.6) 80.2 (6.9) 80.5 (7.0)
Men, % 51.5 56.2 100 100 78.9 87.3 86.7 81.4 75.0 54.1 51.1 45.5 39.1 36.0
Comorbidity, %†
Diagnosed dementia 8.7 6.3 0 0 0 0.6 4.0 1.7 3.4 3.8 5.6 7.1 13.1 13.7
Renal disease 24.1 15.2 0 1.0 0 1.8 6.7 4.6 18.1 9.8 19.0 17.7 31.8 31.0
Previous ischemic stroke 7.5 4.1 0 0 0 0 0 0.2 0 0.3 1.4 1.7 14.5 14.1
Heart failure 37.7 20.2 0 0 5.3 1.6 2.7 3.1 14.2 7.6 26.3 20.8 57.0 51.5
Previous cerebrovascular
event
26.1 13.1 0 1.7 15.8 2.8 13.3 4.3 17.2 7.0 19.8 12.6 34.5 29.6
CHD 51.4 30.9 0 5.5 31.6 10.5 42.7 16.7 44.1 25.8 48.6 35.5 57.2 50.1
Previous VTE 8.3 4.9 0 0 0 0 0 0.4 0.5 1.1 1.4 2.8 15.9 15.2
Malignancy 20.2 15.9 0 4.3 5.3 7.8 18.7 12.1 22.1 15.6 20.9 19.2 19.8 19.6
CHA2DS2-VASc
components, %
CHF-LVD 42.3 23.3 0 0 5.3 2.3 5.3 4.9 18.1 10.3 31.0 24.5 62.1 56.0
Hypertension 87.4 66.8 0 0 21.1 25.2 49.3 36.9 73.5 59.6 91.9 88.4 96.1 94.8
75 y 74.0 61.4 0 0 0 0 36.0 42.9 60.3 62.5 77.4 75.3 83.5 85.0
Diabetes mellitus 36.5 26.6 0 0.1 5.0 2.2 6.7 8.4 21.1 18.0 27.4 32.5 51.2 52.3
Stroke/TIA/VTE 19.3 11.2 0 0 0 0 1.3 0.7 1.0 1.9 2.5 5.8 37.3 36.7
Vascular disease 34.3 17.0 0 0 5.3 0.7 4.0 1.9 9.3 6.4 20.4 16.3 54.7 44.9
65–74 y 21.0 27.7 0 0 42.1 56.2 46.7 42.3 31.4 31.2 20.7 21.7 14.1 13.5
Women 48.5 43.8 0 0 21.1 12.7 13.3 18.6 25.0 45.9 48.9 54.5 60.9 64.0
Rivaroxaban dose, %, mg
10 3.6 5.3 0 3.4 5.3 3.6 5.3 5.2 2.9 5.3 3.6 5.6 3.5 5.7
15 33.0 24.5 0 5.2 5.3 8.0 14.7 17.7 23.0 22.8 30.2 26.9 40.9 35.4
20 63.4 70.2 100 91.3 89.5 88.4 80.0 77.1 74.0 71.9 66.2 67.5 55.6 58.9
MB, Major bleeding; CHD, coronary heart disease; VTE, venous thromboembolism; CHF-LVD, congestive heart failure–left ventricular dysfunction.
*Age is at MB or at end of study participation for patients without major bleeding.
†Individual variables of interest identiﬁed within the 6-month period before MB for cases and within the 6-month period before the end of the study period for non-MB patients.
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CHA2DS2-VASc Scores and Major Bleeding in Atrial Fibrillation Patients Receiving Rivaroxaban Peacock et alscore of 3 or higher, and nearly half of the major bleeding
events occurred in those with a score of 5 or greater
(n¼635). For patients with a CHA2DS2-VASc score
greater than or equal to 2 (considered the “high” category),
mean age increased as scores increased, with an average age
of 80 years for those with the highest scores. The sex
distribution was predominantly male in the lower score
categories, changing to predominantly female in the
score categories of 5 and above. Compared to patients
without major bleeding, those with major bleeding tended
to be older, with higher prevalence of all recorded
comorbidities.
The distribution of rivaroxaban dosing showed that
20 mg (the dose recommended for nonvalvular atrial
ﬁbrillation patients with normal renal function per the
label27) was the predominant dose across all CHA2DS2-
VASc score categories (Table 3). The proportion of
patients receiving a 15-mg dose (the dose recommended
for nonvalvular atrial ﬁbrillation patients with impaired
renal function per the label27) increased as scores
increased, which coincides with the presence of
increasing renal disease and other comorbidities. A small
percentage of patients received the 10-mg dose of
rivaroxaban. Although this dosing is consistent with the
postoperative venous thromboembolism prophylaxis
recommendation of rivaroxaban, the reasons for the
administration of this dose in a nonvalvular atrial
ﬁbrillation cohort are unclear.
Major Bleeding Rates and Characteristics by
CHA2DS2-VASc Scores
Table 3 shows the incidence of major bleeding stratiﬁed
by CHA2DS2-VASc score category. A monotonically
increasing relationship was noted between CHA2DS2-
VASc scores and the incidence rate of major bleeding. The
rate of major bleeding among patients with a score of zero
was 0.30 (95% CI 0.08 to 1.20), with the rate continually
increasing as the CHA2DS2-VASc score increased, reaching
a rate of 5.40 (95% CI 5.00 to 5.84) per 100 person-years
in those with a score of 5 or greater. The major bleeding
rate, stratiﬁed by bleeding location, was highest for
gastrointestinal bleeding events across all CHA2DS2-VASc
score categories (Table 3).
Overall, 41 patients had a major bleeding-related fatal
outcome. Mortality risk generally had a positive
relationship with CHA2DS2-VASc scores (Table 3), with
higher scores indicating higher mortality rates. The mean
age at death by CHA2DS2-VASc score was 60 (SD 0), 67
(SD 0), 75.8 (SD 6.4), 75.7 (SD 8.4), 81.5 (SD 5.7), and
84.5 (SD 4.2) years, for scores 0, 1, 2, 3, 4, and greater
than or equal to 5, respectively.6 Annals of Emergency Medicine Volume -, no. - : - 2016
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hospitalization formajor bleedingwas experienced at a rate of
0.09 (95% CI 0.07 to 0.12) and a case-fatality rate of 3.2%.
Major bleeding incidence rates were also evaluated for
the presence or absence of each CHA2DS2-VASc
component. Results of key ﬁndings from these analyses are
displayed in Table 4 and the Figure. The CHA2DS2-VASc
subgroup with the highest incidence of major bleeding was
those with vascular disease (major bleeding rate was 5.69
[95% CI 5.18 to 6.24] per 100 person-years), followed by
those with a history of stroke, transient ischemic attack, or
venous thromboembolism (major bleeding rate of 5.68
[95% CI 5.01 to 6.43] per 100 person-years).
The subgroup with the highest incidence of
gastrointestinal bleeding was those with vascular disease,
who had a major bleeding rate of 5.04 (95% CI 4.56 to
5.56) per 100 person-years (Figure and Table E1 [available
online at htttp://www.annemergmed.com]). The highest
incidence of intracranial hemorrhage was in the subgroup
of patients with a history of stroke, transient ischemic
attack, or venous thromboembolism, with an incidence of
0.60 (95% CI 0.41 to 0.88) per 100 person-years. Among
patients who experienced a fatal outcome during their
hospitalization for major bleeding, the highest mortality
incidence was in the subgroup with a history of stroke,
transient ischemic attack, or venous thromboembolism, at
0.21 (95% CI 0.11 to 0.39) per 100 person-years
(Table 4), a case-fatality rate of 3.6%.
LIMITATIONS
The current study has limitations. This retrospective
analysis was based on data points that were originally
collected for electronic medical record and accounting orTable 4. Major bleeding and fatal outcome incidence rates, by CHA2D
CHA2DS2-VASc Subcategory
Component
No. (%) of Patients in
Study Population
CHF-LVD 10,676 (23.8)
No CHF-LVD 34,117 (76.2)
Hypertension 30,167 (67.3)
No hypertension 14,626 (32.7)
Diabetes mellitus 11,976 (26.7)
No diabetes mellitus 32,817 (73.3)
Stroke/TIA/VTE 5,138 (11.5)
No stroke/TIA/VTE 39,655 (88.5)
Vascular disease 7,849 (17.5)
No vascular disease 36,944 (82.5)
<65 y 4,803 (10.7)
65–74 y 12,310 (27.5)
75 y 27,680 (61.8)
Women 19,698 (44.0)
Men 25,095 (56.0)
*The MB incidence rate was calculated with person-time for the denominator value (exposu
per 100 person-years.
Volume -, no. - : - 2016claims purposes, rather than research. Additionally,
pharmacy records captured the drug-dispensing
information rather than the actual administration of the
drug, and connecting the use of rivaroxaban to a bleeding
event establishes only a temporal association rather than a
causal relationship. Although major bleeding might be
underreported because of limitations of the databases, there
is also the possibility of capturing false positives, eg, minor
or clinically irrelevant bleeding events.16 Additionally, as
with other database studies, there is a data lag associated
with data processing and releasing for analyses that is
estimated to affect the capture of only a small number of
major bleeding cases, so there should be no material
inﬂuence on the overall study ﬁndings.
Also, although it might have been useful to explore
comparisons between the Hypertension, Abnormal Renal/
Liver Function, Stroke, Bleeding History or Predisposition,
Labile International Normalized Ratio, Elderly (>65
years), Drugs/Alcohol Concomitantly (HAS-BLED) score
and the CHA2DS2-VASc scores to compare assessments of
bleeding risk, international normalized ratio data were not
available in our data set and thus prevented calculation of
HAS-BLED scores.
Finally, major bleeding in this study is not an exact
match with that in clinical trials because the algorithm was
applied retrospectively and relied on information available
in the database. However, the rates and pattern of major
bleeding in this study are generally consistent with the
ﬁndings from the clinical trial for rivaroxaban. For example,
the reported rates of rivaroxaban associated major bleeding
were 3.6 per 100 person-years in patients with nonvalvular
atrial ﬁbrillation in the ROCKET-AF trial26,28 and 2.84
per 100 person-years in this ongoing postmarketingS2-VASc component.
Total Major Bleeding
Incidence Rate* (95% CI)
Fatal Outcome
Incidence Rate (95% CI)
5.12 (4.70–5.56) 0.12 (0.07–0.21)
2.14 (1.99–2.30) 0.08 (0.06–0.12)
3.53 (3.33–3.74) 0.09 (0.06–0.13)
1.20 (1.03–1.40) 0.09 (0.05–0.16)
3.69 (3.37–4.04) 0.09 (0.05–0.16)
2.51 (2.34–2.69) 0.09 (0.06–0.13)
5.68 (5.01–6.43) 0.21 (0.11–0.39)
2.54 (2.39–2.69) 0.08 (0.05–0.11)
5.69 (5.18–6.24) 0.12 (0.06–0.22)
2.25 (2.10–2.41) 0.08 (0.06–0.12)
1.74 (1.37–2.22) 0.05 (0.01–0.21)
2.12 (1.88–2.39) 0.05 (0.03–0.11)
3.30 (3.09–3.51) 0.11 (0.08–0.16)
3.09 (2.86–3.35) 0.08 (0.05–0.13)
2.63 (2.44–2.84) 0.09 (0.06–0.14)
re time at risk) for all ﬁrst major bleeding events within the period under study. Rate is
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Figure. Major bleeding rates by component, by bleeding site. (See Table E1, available online at http://www.annemergmed.com, for
the full complement of data, including CIs.)
CHA2DS2-VASc Scores and Major Bleeding in Atrial Fibrillation Patients Receiving Rivaroxaban Peacock et alpharmacovigilance study. In addition, these studies
demonstrated consistency that gastrointestinal bleeding is
the most common form of major bleeding event, and death
associated with gastrointestinal bleeding is not common (ie,
approximately 0.1 per 100 person-years).
DISCUSSION
Numerous recent studies have validated the predictive
capabilities of CHA2DS2-VASc for assessing risk of
stroke,1,29-32 consistently demonstrating that higher
CHA2DS2-VASc scores are associated with greater risk for
stroke. This is in conﬂict with studies that suggest that
clinicians may withhold anticoagulation therapy from
patients with higher CHA2DS2-VASc scores because of a
concern regarding increased risk of bleeding. Balancing this
risk-beneﬁt trade-off, particularly in high-risk patients,
represents a clinical challenge. Our current analysis showed
a strong relationship between CHA2DS2-VASc scores and
the risk of major bleeding in rivaroxaban users with
nonvalvular atrial ﬁbrillation; as CHA2DS2-VASc scores
increased, so did the incidence of major bleeding.
Our ﬁndings are particularly relevant in the context of
the relationship between CHA2DS2-VASc score and the
risk of ischemic stroke, as demonstrated in other studies,33
and this importance could be reﬂected by 2 aspects: (1) for
any given risk score, the risk of stroke may exceed the risk
of major bleeding, which is a trade-off for prophylactic
antithrombotic therapy; and (2) from a beneﬁt-risk
perspective, stroke represents irreversible harms, whereas
bleeding is often considered transient and manageable.34,35
Lip et al33 determined that CHA2DS2-VASc scores are
associated with a stepwise increase in the estimated rates of
thromboembolism. The difference between their estimated
stroke rates by CHA2DS2-VASc scores and that of the8 Annals of Emergency Medicineincidence of major bleeding by CHA2DS2-VASc score in
our study suggests that the net clinical beneﬁt (risk of
bleeding mitigated by greater risk of stroke) of
anticoagulation with rivaroxaban actually increases as
CHA2DS2-VASc score increases. For example, among
patients with the highest number of risk factors (in the 5
score category), the Lip et al33 analysis demonstrated that
the highest estimated overall (weighted) risk of
thromboembolism or stroke was 8.1% per year compared
with the highest major bleeding rate of 5.40 (95% CI 5.00
to 5.84) per 100 person-years in this study population.
This ﬁnding implies that, despite an increasing risk of
bleeding associated with increasing CHA2DS2-VASc
scores, the risk of stroke is likely much higher, suggesting
that the net clinical beneﬁt may still favor anticoagulation,
even among patients within the highest risk categories.
Although we caution against indirect comparisons across
studies, these empirical data may be informative and
provide a basic framework for physicians to evaluate and
make treatment decisions.
Although both stroke and major bleeding incidence
increase with higher CHA2DS2-VASc scores, the rate of
increase is greatest for estimated stroke risk. We did not
calculate HAS-BLED36 scores for this analysis because an
approximation of bleeding risk is less accurate than using
the actual bleeding rates that were observed for the study
cohort. Although our results in regard to the relationship
between CHA2DS2-VASc scores and bleeding are not
meant to replace existing bleeding risk metrics, we propose
that using CHA2DS2-VASc scores as a possible indicator of
bleeding risk is complementary to other risk measures.
Our report shows that major bleeding was experienced
by a small proportion of rivaroxaban patients with
nonvalvular atrial ﬁbrillation, and among known high-riskVolume -, no. - : - 2016
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CHA2DS2-VASc component was 5.69 (95% CI 5.18 to
6.24) per 100 person-years for patients with vascular
disease. As shown in this study and noted in previous
studies of rivaroxaban, gastrointestinal bleeding events are
the most common source of major bleeding, but the
potential for mortality is low. Conversely, although
intracranial hemorrhage is rare (eg, moderate-risk category)
or uncommon (eg, high-risk category), it has a much higher
association with mortality compared with gastrointestinal
bleeding events. In this analysis, patients with previous
stroke, transient ischemic attack, or venous
thromboembolism represented the cohort who had the
greatest incidence of intracranial hemorrhage and thus were
at greater risk of mortality. In the setting of previous stroke,
transient ischemic attack, or venous thromboembolism,
physicians may balance individual bleeding risks and future
stroke risk, although not undermining that this is the basic
principle for the management of atrial ﬁbrillation patients
in any risk category.
In summary, clinicians must balance the beneﬁt of
stroke prevention with the risk of bleeding when
prescribing anticoagulant therapy. We report that in this
cohort of nearly 45,000 nonvalvular atrial ﬁbrillation
patients receiving rivaroxaban therapy, the CHA2DS2-
VASc score showed a strong relationship with major
hemorrhage. Patients most likely to experience a major
hemorrhage are also those with greater stroke risk and thus
would potentially sustain greater beneﬁt from
anticoagulation than from its avoidance. Additional
research may be warranted.
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Table E1. Site-speciﬁc major bleeding incidence rates, by CHA2DS2-VASc component.
CHA2DS2-VASc Subcategory
Component
No. (%) of Patients in
Study Population
Gastrointestinal Hemorrhage
Incidence Rate* (95% CI)
Intracranial Hemorrhage
Incidence Rate* (95% CI)
Other Site Hemorrhage
Incidence Rate* (95% CI)
CHF-LVD 10,676 (23.8) 4.63 (4.24–5.06) 0.22 (0.14–0.33) 0.27 (0.19–0.39)
No CHF-LVD 34,117 (76.2) 1.78 (1.65–1.93) 0.24 (0.19–0.29) 0.12 (0.09–0.17)
Hypertension 30,167 (67.3) 3.09 (2.90–3.28) 0.26 (0.21–0.32) 0.19 (0.15–0.24)
No hypertension 14,626 (32.7) 0.95 (0.80–1.13) 0.16 (0.11–0.25) 0.09 (0.05–0.16)
Diabetes mellitus 11,976 (26.7) 3.30 (3.00–3.63) 0.19 (0.13–0.28) 0.20 (0.14–0.30)
No diabetes mellitus 32,817 (73.3) 2.12 (1.97–2.29) 0.25 (0.20–0.31) 0.14 (0.11–0.19)
Stroke/TIA/VTE 5,138 (11.5) 4.79 (4.19–5.49) 0.60 (0.41–0.88) 0.30 (0.17–0.51)
No stroke/TIA/VTE 39,655 (88.5) 2.20 (2.06–2.35) 0.19 (0.15–0.24) 0.14 (0.11–0.19)
Vascular disease 7,849 (17.5) 5.04 (4.56–5.56) 0.31 (0.21–0.46) 0.35 (0.24–0.51)
No vascular disease 36,944 (82.5) 1.92 (1.78–2.06) 0.22 (0.17–0.27) 0.12 (0.09–0.16)
<65 y 4,803 (10.7) 1.23 (0.92–1.65) 0.27 (0.14–0.50) 0.24 (0.13–0.46)
65–74 y 12,310 (27.5) 1.88 (1.66–2.13) 0.14 (0.09–0.22) 0.10 (0.06–0.18)
75 y 27,680 (61.8) 2.86 (2.67–3.06) 0.27 (0.21–0.33) 0.17 (0.13–0.23)
Women 19,698 (44.0) 2.68 (2.46–2.92) 0.24 (0.18–0.32) 0.17 (0.12–0.24)
Men 25,095 (56.0) 2.27 (2.09–2.46) 0.22 (0.17–0.29) 0.15 (0.11–0.20)
*The MB incidence rate was calculated using person-time for the denominator value (exposure time at risk) for all ﬁrst major bleeds within the period under study. Rate is per 100
person-years.
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